SCHEMBL600214

SCHEMBL600214

Cc1ccc(S(=O)(=O)OC2CC(COCc3ccccc3)C2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.42
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
CA12 O43570 1/20 0.42
CYP1A2 P05177 1/20 0.42
ATM Q13315 1/20 0.42
CA9 Q16790 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.41
ALDH1A1 P00352 4/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
ELANE P08246 1/20 0.40
AR P10275 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3953338 1.00 CYP3A4 (0.42) CYP3A4BCHEACHECA12CYP1A2
SCHEMBL3958422 1.00 CYP3A4 (0.42) CYP3A4BCHEACHECA12CYP1A2
SCHEMBL22230095 0.85 AR (0.41) CYP3A4BCHEACHECYP1A2ATM
SCHEMBL22230098 0.85 AR (0.41) CYP3A4BCHEACHECYP1A2ATM
SCHEMBL990205 0.83 BCHE (0.44) CYP3A4BCHEACHECA12CYP1A2
SCHEMBL20203214 0.83 BCHE (0.44) CYP3A4BCHEACHECA12CYP1A2
SCHEMBL988821 0.83 BCHE (0.44) CYP3A4BCHEACHECA12CYP1A2
SCHEMBL5788946 0.81 CTSL (0.41) BCHEACHECA9LMNACA1
SCHEMBL29672739 0.81 ALDH1A1 (0.42) CYP3A4BCHEACHECA12CYP1A2
SCHEMBL22283666 0.81 BCHE (0.43) CYP3A4BCHEACHECA12CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062426-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS INC (US) 2026-03-05 US disclosed
EP-4634161-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics Inc. (US) 2025-10-22 EP disclosed
WO-2024130166-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-06-20 WO disclosed
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 US disclosed
US-8114994-B2 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation EMORY UNIVERSITY (US) 2012-02-14 US disclosed
US-20090149416-A1 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-06-11 US disclosed
US-20090111837-A1 USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN PFIZER INC. 2009-04-30 US disclosed
US-7507742-B2 Spirocyclic derivatives PFIZER INC. (US) 2009-03-24 US disclosed
US-7495006-B2 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation EMORY UNIVERSITY (US) 2009-02-24 US disclosed
US-20070129388-A1 Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid PFIZER, INC. 2007-06-07 US disclosed
US-20060223835-A1 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation EMORY UNIVERSITY 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE EGFR, CBL, ERBB2 CYP3A4 4575/4885BCHE 3345/4885ACHE 4653/4885
US-20090149416-A1 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation HAVCR2, PNP, PCNA CYP3A4 728/4885BCHE 672/4885ACHE 4719/4885
US-20060223835-A1 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation HAVCR2, PNP, DCTD CYP3A4 677/4885BCHE 727/4885ACHE 4703/4885
US-20070129388-A1 Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid PDE7A, PDE7B, PDE3A CYP3A4 442/4885BCHE 1550/4885ACHE 82/4885
US-20260062426-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF CCNA1, CCNE1, CCNA2 CYP3A4 1641/4885BCHE 1597/4885ACHE 4455/4885
US-20090111837-A1 USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN PDE7A, PDE7B, PDE3A CYP3A4 3279/4885BCHE 574/4885ACHE 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.